129 related articles for article (PubMed ID: 9733272)
21. Intravesical rhGM-CSF for the treatment of late onset hemorrhagic cystitis after bone marrow transplant.
Vela-Ojeda J; Tripp-Villanueva F; Sanchez-Cortés E; Ayala-Sanchez M; García-Ruiz Esparza MA; Rosas-Cabral A; Gonzalez-Llaven J
Bone Marrow Transplant; 1999 Dec; 24(12):1307-10. PubMed ID: 10627639
[TBL] [Abstract][Full Text] [Related]
22. Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis.
de Miranda Silva C; Fernandes BJ; Donadi EA; Silva LM; Coelho EB; Dantas M; Marques MP; Lanchote VL
J Clin Pharmacol; 2009 Aug; 49(8):965-72. PubMed ID: 19546252
[TBL] [Abstract][Full Text] [Related]
23. Bone marrow transplantation in children with severe aplastic anemia using a conditioning regimen containing 3 Gy of total body irradiation, cyclophosphamide with or without antithymocyte globulin.
Inagaki J; Nagatoshi Y; Kawano Y; Saito Y; Takahashi D; Nagayama J; Shinkoda Y; Hirata H; Okamura J
Pediatr Transplant; 2007 Mar; 11(2):180-6. PubMed ID: 17300498
[TBL] [Abstract][Full Text] [Related]
24. Enantioselective induction of cyclophosphamide metabolism by phenytoin.
Williams ML; Wainer IW; Embree L; Barnett M; Granvil CL; Ducharme MP
Chirality; 1999; 11(7):569-74. PubMed ID: 10423284
[TBL] [Abstract][Full Text] [Related]
25. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
[TBL] [Abstract][Full Text] [Related]
26. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
Bhalla KN; Kumar GN; Walle UK; Ibrado AM; Javed T; Stuart RK; Reed C; Arbuck SG; Walle T
Clin Cancer Res; 1999 Jul; 5(7):1723-30. PubMed ID: 10430075
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of (R)- and (S)-cyclophosphamide and their dechloroethylated metabolites in cancer patients.
Williams ML; Wainer IW; Granvil CP; Gehrcke B; Bernstein ML; Ducharme MP
Chirality; 1999; 11(4):301-8. PubMed ID: 10224657
[TBL] [Abstract][Full Text] [Related]
28. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
30. Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma.
Erlichman C; Soldin SJ; Hardy RW; Thiessen JJ; Sturgeon JF; Fine S; Baskerville T
Arzneimittelforschung; 1988 Jun; 38(6):839-42. PubMed ID: 3178926
[TBL] [Abstract][Full Text] [Related]
31. PLasma half-life and urinary excretion of cyclophosphamide in children.
Sladek NE; Priest J; Doeden D; Mirocha CJ; Pathre S; Krivit W
Cancer Treat Rep; 1980; 64(10-11):1061-6. PubMed ID: 7459891
[TBL] [Abstract][Full Text] [Related]
32. Validation of urinary excretion of cyclophosphamide as a biomarker of exposure by studying its renal clearance at high and low plasma concentrations in cancer patients.
Hedmer M; Höglund P; Cavallin-Ståhl E; Albin M; Jönsson BA
Int Arch Occup Environ Health; 2008 Jan; 81(3):285-93. PubMed ID: 17579883
[TBL] [Abstract][Full Text] [Related]
33. Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism.
Busse D; Busch FW; Schweizer E; Bohnenstengel F; Eichelbaum M; Fischer P; Schumacher K; Aulitzky WE; Kroemer HK
Cancer Chemother Pharmacol; 1999; 43(3):263-8. PubMed ID: 9923558
[TBL] [Abstract][Full Text] [Related]
34. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients.
Kim HJ; Park CY; Park YH; Kim YJ; Kim DW; Min WS; Kim CC
Bone Marrow Transplant; 2003 Jan; 31(2):79-86. PubMed ID: 12621487
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients.
Staatz CE; Willis C; Taylor PJ; Tett SE
Clin Pharmacol Ther; 2002 Dec; 72(6):660-9. PubMed ID: 12496747
[TBL] [Abstract][Full Text] [Related]
36. NTP Technical Report on the comparative toxicity studies of allyl acetate (CAS No. 591-87-7), allyl alcohol (CAS No. 107-18-6) and acrolein (CAS No. 107-02-8) administered by gavage to F344/N rats and B6C3F1 mice.
Irwin RD
Toxic Rep Ser; 2006 Jul; (48):1-73, A1-H10. PubMed ID: 17160105
[TBL] [Abstract][Full Text] [Related]
37. Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results.
Gaziev D; Galimberti M; Polchi P; Angelucci E; Giardini C; Baronciani D; Andreani M; Persini B; Erer B; Sodani P; Manna M; Nicolini G; Visani G; Lucarelli G;
Bone Marrow Transplant; 2002 Jan; 29(1):1-8. PubMed ID: 11840137
[TBL] [Abstract][Full Text] [Related]
38. Effects of propylthiouracil on urinary metabolites of cyclophosphamide in rats.
Chijiiwa K; Linscheer WG; Raheja KL; Cho C
Cancer Res; 1983 Nov; 43(11):5205-9. PubMed ID: 6616456
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow transplantation from matched siblings in patients with fanconi anemia utilizing low-dose cyclophosphamide, thoracoabdominal radiation and antithymocyte globulin.
Ayas M; Solh H; Mustafa MM; Al-Mahr M; Al-Fawaz I; Al-Jefri A; Shalaby L; Al-Nasser A; Al-Sedairy R
Bone Marrow Transplant; 2001 Jan; 27(2):139-43. PubMed ID: 11281382
[TBL] [Abstract][Full Text] [Related]
40. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
Byrne JL; Stainer C; Cull G; Haynes AP; Bessell EM; Hale G; Waldmann H; Russell NH
Bone Marrow Transplant; 2000 Feb; 25(4):411-7. PubMed ID: 10723585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
